Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pluvicto in mCRPC with Super Scan
NCT06972628Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoints: Radiographic Progression-Free Survival at 24 months, Overall Survival at 24 months and 2 more. Started May 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06972628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06972628.